Full Press Release Details
Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit.
IMMP
Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
Key Takeaway: Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)